UTHR News and Press, United Therapeutics Corporation From 06/19/23

2023-06-19 05:16:46 ET Summary Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on PBE, a genomics ETF. 10 healthcare stocks cheaper than their peers in Ju...

First-of-its-kind distribution and warehouse center introduces a holistic approach to operations and energy management Facility poised to support United Therapeutics’ near-term growth objective of doubling its revenue run rate to $4 billion annually by the middle of this decade ...

2023-05-10 10:47:03 ET Summary MannKind Corporation is a U.S. biopharmaceutical developer and marketer of inhaled therapeutics for endocrine and rare lung diseases in the United States. MannKind topped analysts on earnings and revenues on a strong increase in revenue thanks to rob...

2023-05-04 16:37:47 ET Summary United Therapeutics Corporation came in with a strong topline in Q1 FY'23, growing 10% YoY. The Tyvaso label was the star, growing 40% or $66mm over the 12 months. This shrugs off major threats from the label's competitors. The market has rew...

2023-05-03 15:06:09 ET United Therapeutics Corporation (UTHR) Q1 2023 Earnings Conference Call May 03, 2023, 09:00 AM ET Company Participants Dewey Steadman - Head-Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - ...

2023-05-03 06:05:34 ET United Therapeutics press release ( NASDAQ: UTHR ): Q1 GAAP EPS of $4.86 beats by $0.36 . Revenue of $506.9M (+9.7% Y/Y) misses by $7.47M . “The hard work and determination of our over 1,000 Unitherians during the first quarter of ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2023. Total revenues in the first quarter of 2023 grew 10% year-over-year to $506.9 million, compared to $461.9 million in the first quarter of 2022....

2023-05-02 13:05:01 ET United Therapeutics ( NASDAQ: UTHR ) is scheduled to announce Q1 earnings results on Wednesday, May 3rd, before market open. The consensus EPS Estimate is $4.71 (-6.4% Y/Y) and the consensus Revenue Estimate is $514.37M (+11.4% Y/Y). Over the las...

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will report its first quarter 2023 financial results before the market opens on Wednesday, May 3, 2023. United Therapeutics will host a public webcast Wednesday, May 3, 2023, at 9:00 a.m. Eastern Time. The webcast wil...

Results from the EXPEDITE study of Remodulin ® induction prior to Orenitram ® therapy to be presented at ATS Baseline patient data from the TETON studies of Tyvaso ® Inhalation Solution in patients with idiopathic pulmonary fibrosis to be presented at AT...